M N Dworzak

Summary

Affiliation: University of Vienna
Country: Austria

Publications

  1. ncbi Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Exp Hematol 27:673-81. 1999
  2. ncbi CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Br J Haematol 105:690-5. 1999
  3. ncbi Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Leuk Lymphoma 38:295-308. 2000
  4. ncbi Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Blood 92:3203-9. 1998
  5. ncbi CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease
    M N Dworzak
    Children s Cancer Research Institute, St Anna Children s Hospital, Vienna, Austria
    Leukemia 18:703-8. 2004
  6. ncbi Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis
    A Attarbaschi
    1St Anna Children's Hospital, Vienna, Austria
    Leukemia 18:1611-6. 2004
  7. ncbi Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Blood 83:415-25. 1994
  8. ncbi Immunological detection of minimal residual disease in acute lymphoblastic leukemia
    M N Dworzak
    Forschungsinstitut für krebskranke Kinder, St Anna Kinderspital, Wien, Austria
    Onkologie 24:442-8. 2001
  9. ncbi PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13)
    S Strehl
    1CCRI, Children's Cancer Research Institute, St Anna Kinderspital, Kinderspitalgasse 6, A-1090 Vienna, Austria
    Leukemia 17:1121-3. 2003
  10. ncbi Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group
    C Prucker
    Department of Paediatric Haematology and Oncology, St Anna Children s Hospital, Vienna, Austria
    Leukemia 23:1264-9. 2009

Collaborators

  • H Gadner
  • G Fritsch
  • A Biondi
  • R Ratei
  • N Jones
  • W D Ludwig
  • G Basso
  • G Steiner
  • Krzysztof Kałwak
  • O A Haas
  • A Attarbaschi
  • G Mann
  • G Fuka
  • S Strehl
  • C Prucker
  • Th Lion
  • G Gaipa
  • R Grausenburger
  • U Kaindl
  • A Inthal
  • R Panzer-Grümayer
  • E Bauer
  • D Stoiber
  • H P Kantner
  • M Kauer
  • G Krapf
  • B Ausserer
  • H Haas
  • W Knapp
  • K Dieckmann
  • R Potter
  • U Potschger
  • O Stöllinger
  • B Meister
  • W Kaulfersch
  • J Rücke
  • H Grienberger
  • K H Kärcher
  • H Berger
  • R Ploier
  • R Jones
  • T Ebetsberger
  • C Peters
  • R Hawlicek
  • I Slavc
  • G Muller
  • H Messner
  • C Urban
  • O Jürgenssen
  • P Krepler
  • K Schmitt
  • W F Pickl
  • W Tulzer
  • E Pichler
  • R Kurz
  • P Hocker
  • I Mutz
  • U Busch
  • Ch Urban
  • F M Fink
  • M Steiner
  • V Jeitler
  • T Coliva
  • M Veltroni
  • G Cazzaniga
  • A Faini
  • M G Valsecchi
  • O Maglia
  • B Michelotto
  • V Leoni
  • C Bugarin
  • M M Trebo
  • K Kalwak

Detail Information

Publications13

  1. ncbi Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Exp Hematol 27:673-81. 1999
    ..Comparative phenotype mapping thus allows one to distinguish between normal and leukemic cells, and we show that it may enable rapid, specific, and quantitative detection of residual/resurgent leukemia in BCP-ALL...
  2. ncbi CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Br J Haematol 105:690-5. 1999
    ..In summary, we found that paediatric B-lineage malignancies display remarkable synchrony regarding the levels of CD99 expression compared to their putative normal counterparts...
  3. ncbi Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Leuk Lymphoma 38:295-308. 2000
    ....
  4. ncbi Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Blood 92:3203-9. 1998
    ..This raises the chance to follow the sequential events heralding B-cell commitment in the most immature precursors by correlating phenotypic and genetic differentiation markers...
  5. ncbi CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease
    M N Dworzak
    Children s Cancer Research Institute, St Anna Children s Hospital, Vienna, Austria
    Leukemia 18:703-8. 2004
    ..002% of nucleated BM cells in patients with non-T ALL). We conclude that CD99 is a highly informative tool for MRD detection in T-ALL, bearing the advantage of surface expression in contrast to TdT...
  6. ncbi Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis
    A Attarbaschi
    1St Anna Children's Hospital, Vienna, Austria
    Leukemia 18:1611-6. 2004
    ..We also provided preliminary evidence that the deletion of the nontranslocated TEL allele may adversely influence the clinical course of TEL/AML1+ ALL...
  7. ncbi Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood
    M N Dworzak
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Blood 83:415-25. 1994
    ..We speculate that these observations imply a functional significance of MIC2 in the network of hematopoietic adhesion pathways...
  8. ncbi Immunological detection of minimal residual disease in acute lymphoblastic leukemia
    M N Dworzak
    Forschungsinstitut für krebskranke Kinder, St Anna Kinderspital, Wien, Austria
    Onkologie 24:442-8. 2001
    ..Concluding remarks further relate to technical issues which may allow to simplify the approach in the future which should augment also its economic efficiency...
  9. ncbi PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13)
    S Strehl
    1CCRI, Children's Cancer Research Institute, St Anna Kinderspital, Kinderspitalgasse 6, A-1090 Vienna, Austria
    Leukemia 17:1121-3. 2003
    ..As the PAX5 and ETV6 genes are localized at 9p13 and 12p13, respectively, the cytogenetic description of the dic(9;12)-PAX5/ETV6 rearrangement should be refined to dic(9;12)(p13;p13)...
  10. ncbi Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group
    C Prucker
    Department of Paediatric Haematology and Oncology, St Anna Children s Hospital, Vienna, Austria
    Leukemia 23:1264-9. 2009
    ..We also identified a distinct subset of patients who are especially prone to death and may need a special focus when receiving intense chemotherapy...
  11. ncbi Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts
    G Fuka
    Children s Cancer Research Institute, St Anna Kinderkrebsforschung, Medical University Vienna, Vienna, Austria
    Leukemia 26:927-33. 2012
    ..Importantly, these results provide a first rationale and justification for targeting the fusion gene and the PI3K/AKT/mTOR pathway therapeutically...
  12. ncbi Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection
    G Gaipa
    Centro Ricerca M Tettamanti, , Ospedale San Gerardo, Via Donizetti 106, 20052 Monza, Milan, Italy
    Leukemia 19:49-56. 2005
    ..Investigators should take this phenomenon into account in order to avoid pitfalls in flow cytometric MRD studies...
  13. ncbi Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia
    A Attarbaschi
    Leukemia 21:584-6. 2007